leisure time -WSS

leisure time

author：focus 2025-09-30 17:46:19 - browse：772

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： STAT Readout Newsletter: Today's biggest biotech updates

entertainment

WSS

UnitedHealth’s board chair also owns a personal investment firm

NIH confirmation hearing shows politicization of research

How climate

Police still searching for prisoner who escaped from NYC hospital

Friends ask where James Watson's attitudes about race came from

Lawmakers consider Medicare pay reforms for doctors

hotspot

leisure time

explore

Hepatitis C has a cure — but many Americans still lack access to it

NIH confirmation hearing shows politicization of research

Hollywood unions extend contract negotiations for actors

Beam Therapeutics to lay off 20% of its staff, re

Hollywood unions extend contract negotiations for actors

The EU Joint Clinical Assessment needs to live up to its promise

The cancer drug shortage isn’t new — and neither are the solutions

Methadone doses haven’t kept up in the age of fentanyl

Novavax promises a turnaround & Lilly roils the obesity market

The best solution to the drug shortages problem

Wikipedia

HHS leader on health, climate change and biopharma emissions

Police still searching for prisoner who escaped from NYC hospital

Police still searching for prisoner who escaped from NYC hospital

FDA struggles to regulate food additives, sometimes for decades

A biotech analyst on neuroscience, placebo effect, not over

Pharmacists can make shortage drugs, but at what cost?

entertainment

entertainment

hotspot

hotspot